Making the EFPIA Physicians Spend Numbers Talk!

See what the spend data may be telling us.

1 – Summary of Numbers from 2015 EFPIA disclosure2 – What the numbers may tell us if we look closer3 – EU wide analytics – case study 13 – Country wide analytics – case study 24 – Company wide analytics – case study 35 – Business and compliance considerations6 – Q & A

Agenda:

Summary of Numbers from 2015 EFPIA dataThe EFPIA transparency directive received its first data set in June of 2015, some 3 months ago. During this time press has questioned the rates of consent received from physicians in reporting spend details, and questioned if the program met its objective.

We will present many numbers – you draw your own conclusions…

One view of consent ratio’s

35%

65%

Summary of Numbers from 2015 EFPIA data• The national press has reported that in in UK a total

spend of £300+ M were reported where 70% of physicians consented to have their data included. • In Germany 20,000 of the 71,000 reportable

physicians consented. With data disclosed by 54 companies that represent 75% of the market.• We found that the ratio’s may be lower.

What the numbers may be telling us if we look closerAverages and generalizations are convenient but they may not reveal the true color of disclosure.

Three case studies:

EU wide Country wide (Germany)Company wide (masked)

EU wide analytics – case study 1EU wide data restricted to 4 countries for ease of sharing:GermanySpainItalyUK

EU wide analytics – case study 1At the national level across countries – the ratio’s and spend priorities begin to tell a story where spend patterns may show a regional focus.

Here is are several snapshots by spend type:

Total Spend: Germany has the largest spend EURO 576M

Donations & Grants: UK has the largest spend EURO 25MDonations & Grants: Germany has the lowest spend EURO 8M

Fees: Spain has the largest spend EURO 297MFees: UK has the lowest spend EURO 34M

Registration Fees: Italy has the largest spend EURO 24MRegistration Fees: UK has the lowest spend EURO 3M

Country wide analytics – case study 2Germany – der Spiegel’s analysis claims that:• 75% of pharmaceutical industry drug manufacturers reported

25% of spend data not reported • *20,000 out of 70,000 physicians (33%) consented

66% of physician level spend not reported

qordata noted that the transparency in Germany was “about” 7% and not 33%.

Here are the numbers qordata’s analytics engine offered.

* of those who reported

575M 20,000

Changing the criteria for consent ratio• Criteria: Level of visibility into spend as the bases for evaluating the

affect of consent.

• Formula: Total amount of spend (for consented physicians) /Total amount of General spend (consented + non consented)*Research payments excluded from the formula

Result:

CalculationCompany Name Consent Amount Non Consent Amount Consent %Alexion 0.00 € 756,814.00 € 0.00%Seqirus GmbH 0.00 € 7,125.00 € 0.00%Aegerion Pharmaceuticals GmbH 1,653.40 € 0.00 € 100.00%MediGene AG 34,033.77 € 1,943.60 € 94.60%Baxter Deutschland GmbH 38,097.74 € 161,070.81 € 19.13%Eisai GmbH 39,453.59 € 214,496.26 € 15.54%GlaxoSmithKline GmbH & Co. KG 130,649.08 € 266,433.34 € 32.90%Lundbeck GmbH 189,041.12 € 809,967.23 € 18.92%Shire 218,132.01 € 878,083.34 € 19.90%Roche Pharma AG 252,433.83 € 2,692,411.98 € 8.57%ACTELION Pharmaceuticals Deutschland GmbH 269,632.02 € 620,066.39 € 30.31%

MSD SHARP & DOHME GmbH 1,978,646.18 € 4,672,909.29 € 29.75%Berlin-Chemie AG 2,106,647.64 € 5,824,356.26 € 26.56%Novartis Pharma GmbH 3,570,612.08 € 8,605,871.45 € 29.32%

23,099,253.78 € 257,848,556.46 € 29.57%

----------------------------------- ----- ------- --

Aggregated Consent %:

23,099,253.78 € /257,848,556.46 € =

0.089584577 or 9%

75% of pharmaceutical industry drug manufacturers reported

25% of spend data not reported

Absolute Consent %:

75% of 9% =0.067188433 or 6.7%

Germany

Italy

Der SpiegelAny volunteers willing to contact the newspaper and help enlighten them?

Company wide analytics – case study 3Company name masked – main idea is to illustrate how data analytics can help know the full story and gain insight.

Is the regional spend, spend ratios & TOV amount in line …

Ability to evaluate influences…

HCO Analysis …

Compliance – know where you stand in the context of the industryConsider programs to increase your absolute consent %Consider programs to increase your aggregate consent %Consider programs to increase your nominal consent %

Business – Spend comparison by drug, device, specialty, physician, HCO, etc.Understand your spend end to endMonitor your spend end to endEffectively compare your spend against the industry

Business & Compliance considerations